By Professor David Thomas

Journal articles

Gaughran G; Body A; Thavaneswaran S; Bellinger M; Harris SJ; Davies AG; Huang ML; Kee D; Thomas D, 2025, '82P Y220C, a rare but druggable TP53 mutation: A molecular landscape in an Australian context', ESMO Open, 10, pp. 105432 - 105432, http://dx.doi.org/10.1016/j.esmoop.2025.105432

Lin FP; Itchins M; Chinchen S; Thavaneswaran S; Mersiades A; Aberoumand M; Nagrial A; Xu W; Takhar HS; Harrup RA; Desai J; Cummins M; Espinoza D; Kansara M; Yip S; Lee CK; Simes J; Solomon BJ; Pavlakis N; Thomas D, 2025, '996P Phase II trial of alectinib in ALK-altered solid tumours and NSCLC with negative standard care testing: Australian molecular screening and therapeutics (MoST) substudy 14', Annals of Oncology, 36, pp. s651, http://dx.doi.org/10.1016/j.annonc.2025.08.1565

Srinivasa S; Fletcher C; Zhang BY; Goodwin A; Palme CE; Bhadri VA; Grimison PS; Thomas DM; Maclean F; Gupta R; Connolly EA, 2025, 'EP300::VGLL3 rhabdomyosarcoma: a potential distinct indolent adult rhabdomyosarcoma subtype', ESMO Rare Cancers, 2, pp. 100012, http://dx.doi.org/10.1016/j.esmorc.2025.100012

Lin FP-Y; Goldstein D; Grady JP; Napier C; Thavaneswaran S; Pitiyarachchi O; Kansara M; Chantrill LA; Sjoquist K; Thornton K; Raina A; Magenau A; Simes J; Ballinger ML; Sharbeen G; Timpson P; Pajic M; Phillips P; Thomas DM, 2025, 'Genomic and outcome analysis of recurrent versus de novo metastatic pancreatic ductal adenocarcinoma (PDAC) receiving systemic therapy: Results from the Australian MoST and CaSP screening programs.', Journal of Clinical Oncology, 43, pp. 4120 - 4120, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.4120

Gaughran G; Zaheed M; Harris SJ; Napier C; Yap M; Bellinger M; Grady J; Kee D; Caillet V; Davies A; Thavaneswaran S; Thomas DM, 2025, 'HIF2α pathway aberrations across tumour types: A rare but actionable entity with high germline conversion', ANNALS OF ONCOLOGY, 36, http://dx.doi.org/10.1016/j.annonc.2025.10.1192

Ballinger M; Zaheed M; Carpenter E; Napier C; Cops E; Ferris N; Moodie K; Milner B; Moses D; Dwarte T; Poplawski N; Dow E; Tucker K; Trainer A; James P; Thomas D, 2025, 'LONG TERM SURVEILLANCE OUTCOMES IN SARCOMA PREDISPOSITION SYNDROMES', ESMO Rare Cancers, 4, pp. 100044 - 100044, http://dx.doi.org/10.1016/j.esmorc.2025.100044

Lin FP-Y; Huang ML; Grady JP; Thavaneswaran S; Kansara M; Napier C; Ballinger ML; Simes J; Thomas DM, 2025, 'Machine learning–based classification of cancer types using genomic profiling data from the Australian Molecular Screening and Therapeutics (MoST) program.', Journal of Clinical Oncology, 43, pp. e13683 - e13683, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.e13683

Pavlakis N; Lee CK; Ballinger ML; Brown CSB; Grady JP; Lin F; Thavaneswaran S; Mersiades AJ; Di-Xin Zhou D; Lee J; John T; Napier CE; Cummins MM; Collignon E; Sebastian L; Turnbull OMH; Simes J; Thomas DM; Solomon BJ, 2025, 'P2.06.61 ASPiRATION. Australian Nationwide Cohort Study to Assess Impact of Comprehensive Genomic Profiling in Metastatic Lung Cancer', Journal of Thoracic Oncology, 20, pp. S318 - S319, http://dx.doi.org/10.1016/j.jtho.2025.09.595

Kohlmann W; Curtin K; Madsen MJ; Camp NJ; Jeter JM; Ballinger ML; Thomas DM; Garber JE; Schiffman JD, 2025, 'Population-based assessment of leiomyosarcoma (LMS) and cancers in the Li-Fraumeni syndrome (LFS) spectrum: Implications for genetic testing criteria.', Journal of Clinical Oncology, 43, pp. 11570 - 11570, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.11570

Gaughran G; Mamrot J; Fitzgerald S; Kee D; Napier C; Harris SJ; Thavaneswaran S; Grady J; Davies A; Bellinger M; Thomas DM, 2025, 'Real-world experience of liquid biopsy (LBx) vs tissue-based comprehensive genomic profiling (tCGP)', ANNALS OF ONCOLOGY, 36, http://dx.doi.org/10.1016/j.annonc.2025.10.1211

Thavaneswaran S; Lin F; Grady JP; Espinoza D; Huang ML; Chinchen S; Sebastian L; Kansara M; Mersiades T; Lee CK; Desai J; Grimison P; Brown M; Millward M; Harrup R; O’Byrne K; Nagrial A; Craft P; Simes J; Joshua AM; Thomas DM, 2024, 'A signal-seeking phase 2 study of Trastuzumab emtansine in tumours harbouring HER2 amplification or mutation', Npj Precision Oncology, 8, http://dx.doi.org/10.1038/s41698-024-00698-4

Collet L; Telouk P; Albarede F; Girodet M; Maqua C; Rogasik M; Ducimetière F; Tabone-Eglinger S; Brahmi M; Dufresne A; Thomas DM; Ballinger ML; Blay JY; Ray-Coquard I, 2024, 'Connecting the changing trace elements spectrum and survival in sarcoma: a pilot study', Metabolomics, 20, http://dx.doi.org/10.1007/s11306-024-02178-z

Takeda K; Nakayama M; Hayakawa Y; Kojima Y; Ikeda H; Imai N; Ogasawara K; Okumura K; Thomas DM; Smyth MJ, 2024, 'Correction to: IFN-γ is required for cytotoxic T cell-dependent cancer genome immunoediting (Nature Communications, (2017), 8, 1, (14607), 10.1038/ncomms14607)', Nature Communications, 15, http://dx.doi.org/10.1038/s41467-024-53456-2

Deng F; Li Y; Yang B; Sang R; Deng W; Kansara M; Lin F; Thavaneswaran S; Thomas DM; Goldys EM, 2024, 'Topological barrier to Cas12a activation by circular DNA nanostructures facilitates autocatalysis and transforms DNA/RNA sensing', Nature Communications, 15, pp. 1818, http://dx.doi.org/10.1038/s41467-024-46001-8

Gianferante DM; Moore A; Spector LG; Wheeler W; Yang T; Hubbard A; Gorlick R; Patiño-Garcia A; Lecanda F; Flanagan AM; Amary F; Andrulis IL; Wunder JS; Thomas DM; Ballinger ML; Serra M; Hattinger C; Demerath E; Johnson W; Birmann BM; De Vivo I; Giles G; Teras LR; Arslan A; Vermeulen R; Sample J; Freedman ND; Huang WY; Chanock SJ; Savage SA; Berndt SI; Mirabello L, 2024, 'Genetically inferred birthweight, height, and puberty timing and risk of osteosarcoma', Cancer Epidemiology, 92, http://dx.doi.org/10.1016/j.canep.2023.102432

Best MC; Butow P; Savard J; Newson AJ; Campbell R; Vatter S; Napier CE; Bartley N; Tucker K; Ballinger ML; Thomas DM; Butow P; Tucker K; Juraskova I; Schlub T; Davies G; Meiser B; Goldstein D, 2024, 'From ownership to custodianship of tumor biopsy tissue in genomic testing: A mixed methods study of patient views', Oncologist, 29, pp. e1169 - e1179, http://dx.doi.org/10.1093/oncolo/oyae074

Dziadziuszko R; Barlesi F; Kim JE; Gadgeel SM; Krzakowski M; Jeong JH; Daniele G; Chen D; Hu Y; Wilson TR; Simmons BP; Thomas DM, 2024, 'Atezolizumab in patients (pts) with tumor mutational burden (TMB)–high tumors from the TAPISTRY trial.', Journal of Clinical Oncology, 42, pp. lba2509 - lba2509, http://dx.doi.org/10.1200/jco.2024.42.17_suppl.lba2509

Barjesteh van Waalwijk van Doorn-Khosrovani S; Kholmanskikh Van Criekingen O; Koole S; Thomas DM; Gelderblom H, 2024, 'Testing dilemmas in the clinic: Lessons learned from biomarker-based drug development', Cancer Cell, 42, pp. 923 - 929, http://dx.doi.org/10.1016/j.ccell.2024.05.014

Thomas DM; Daniele G; Kim JE; Gadgeel SM; Ahn ER; Paz-Ares LG; Prenen H; Chen D; Fang J; Wilson TR; Simmons BP; Barlesi F, 2024, 'Ipatasertib in patients with AKT1/2/3 mutation-positive (AKTmut) tumors: TAPISTRY study.', Journal of Clinical Oncology, 42, pp. 3092 - 3092, http://dx.doi.org/10.1200/JCO.2024.42.16_suppl.3092

Kim JE; Thomas D; Gadgeel S; Corassa M; Tan TJ; Girda E; Richards D; Tejpar S; Chen D; Fang J; Patel S; Wilson TR; Barlesi F, 2024, 'Abstract CT265: Trastuzumab emtansine in patients (pts) with HER2 mutation-positive (HER2 mut ) tumors: TAPISTRY study', Cancer Research, 84, pp. ct265 - ct265, http://dx.doi.org/10.1158/1538-7445.am2024-ct265

Mirabello L; Egolf LE; Zhu B; Gianferante DM; Wang K; Li SA; Machiela MJ; Spector LG; Schiffman JD; Sabo A; Renwick A; Martin-Giacalone B; Scheurer ME; Plon S; Hawkins D; Venkatramani R; Stewart D; Morton LM; Hudson MM; Armstrong GT; Bhatia S; Dean M; Janeway KA; Patino-Garcia A; Lecanda F; Serra M; Hattinger C; Scotlandi K; Flanagan AM; Amary F; Andrulis IL; Wunder JS; Ballinger ML; Thomas DM; Delattre O; Hubbard AK; Liu J; Luo W; Hicks BD; Yeager M; Rafati M; Huang W-Y; Landi MT; Lori A; Diver R; Savage SA; Chanock SJ; Lupo PJ, 2024, 'Underlying germline genetic architecture of pediatric sarcomas: Evaluating the role of common and rare variants in 4,160 patients', CANCER RESEARCH, 84, http://dx.doi.org/10.1158/1538-7445.AM2024-775

Freeman B; Peters MJ; Bittoun R; Brightwell R; English DR; Thomas DP; Otlowski MFA; Zwar NA; Chamberlain C, 2024, 'National Health and Medical Research Council statement on electronic cigarettes: 2022 update', Medical Journal of Australia, 220, pp. 100 - 106, http://dx.doi.org/10.5694/mja2.52163

Ringborg U; von Braun J; Celis J; Baumann M; Berns A; Eggermont A; Heard E; Heitor M; Chandy M; Chen CJ; Costa A; De Lorenzo F; De Robertis EM; Dubee FC; Ernberg I; Gabriel M; Helland Å; Henrique R; Jönsson B; Kallioniemi O; Korbel J; Krause M; Lowy DR; Michielin O; Nagy P; Oberst S; Paglia V; Parker MI; Ryan K; Sawyers CL; Schüz J; Silkaitis K; Solary E; Thomas D; Turkson P; Weiderpass E; Yang H, 2024, 'Strategies to decrease inequalities in cancer therapeutics, care and prevention: Proceedings on a conference organized by the Pontifical Academy of Sciences and the European Academy of Cancer Sciences, Vatican City, February 23–24, 2023', Molecular Oncology, 18, pp. 245 - 279, http://dx.doi.org/10.1002/1878-0261.13575

Mersiades AJ; Solomon Benjamin J; Thomas David M; Lee CK; Cummins MM; Sebastian L; Ballinger ML; Collignon E; Turnbull OMH; Yip S; Morton RL; Brown C; Wheeler PJ; Itchins M; Simes RJ; Pavlakis N, 2024, 'ASPiRATION: Australian Observational Cohort Study of Comprehensive Genomic Profiling in Metastatic Lung Cancer Tissue', Future Oncology, 20, pp. 361 - 371, http://dx.doi.org/10.2217/fon-2023-0366

Fortuno C; Feng BJ; Carroll C; Innella G; Kohlmann W; Lázaro C; Brunet J; Feliubadaló L; Iglesias S; Menéndez M; Teulé A; Ballinger ML; Thomas DM; Campbell A; Field M; Harris M; Kirk J; Pachter N; Poplawski N; Susman R; Tucker K; Wallis M; Williams R; Cops E; Goldgar D; Investigators KCF; James PA; Spurdle AB, 2024, 'Cancer Risks Associated With TP53 Pathogenic Variants: Maximum Likelihood Analysis of Extended Pedigrees for Diagnosis of First Cancers Beyond the Li-Fraumeni Syndrome Spectrum', JCO Precision Oncology, 8, http://dx.doi.org/10.1200/PO.23.00453

Cho D; Lord SJ; Ward R; IJzerman M; Mitchell A; Thomas DM; Cheyne S; Martin A; Morton RL; Simes J; Lee CK, 2024, 'Criteria for assessing evidence for biomarker-targeted therapies in rare cancers—an extrapolation framework', Therapeutic Advances in Medical Oncology, 16, http://dx.doi.org/10.1177/17588359241273062

Sargen MR; Kim J; Haley JS; Barker HP; Mundra PA; Ballinger ML; Thomas DM; Carey DJ; Goldstein AM; Stewart DR, 2024, 'Increased frequency of CHEK2 germline pathogenic variants among individuals with dermatofibrosarcoma protuberans', Genetics in Medicine Open, 2, http://dx.doi.org/10.1016/j.gimo.2024.101895

Klein O; Carlino M; Brown M; Harris SJ; Gunjur A; Underhill CR; Zielinski R; Kee D; Lam W-S; Chan H; Harrup RA; So J; Collins I; Michael M; Torres J; Palmer JB; Thomas D; Wilkie K; Cebon J; Nagrial A, 2024, '282P Nivolumab and ipilimumab combination treatment in advanced intrahepatic cholangiocarcinoma and gallbladder cancer', Annals of Oncology, 35, pp. s119, http://dx.doi.org/10.1016/j.annonc.2024.05.288

Klein O; Carlino MS; Michael M; Underhill CR; So J; Kee D; Antill Y; Lam W-S; Chan H; Harrup RA; Hamilton A; Palmer JB; Thomas DM; Wilkie K; Cebon J; Gao B, 2024, '713MO Nivolumab and ipilimumab combination treatment in advanced gynaecological clear cell cancers: Results from the phase II MoST-CIRCUIT trial', Annals of Oncology, 35, pp. s546 - s547, http://dx.doi.org/10.1016/j.annonc.2024.08.775

Klein O; Gao B; Chan H; Michael M; Zielinski R; So J; Harris SJ; Kee D; Collins IM; Lam W-S; Lyle M; Underhill CR; Brown M; Harrup RA; Wong SF; Palmer JB; Thomas D; Wilkie K; Cebon J; Carlino MS, 2024, '998MO Nivolumab and ipilimumab combination treatment in advanced dMMR/MSI-H noncolorectal cancers: Results from the phase II MoST-CIRCUIT study', Annals of Oncology, 35, pp. s679 - s680, http://dx.doi.org/10.1016/j.annonc.2024.08.1057

Walpole IR; Zaman FY; Zhao P; Marshall VM; Lin FP; Thomas DM; Shackleton M; Antolin AA; Ameratunga M, 2024, 'Computational repurposing of oncology drugs through off‐target drug binding interactions from pharmacological databases', Clinical and Translational Medicine, 14, pp. e1657, http://dx.doi.org/10.1002/ctm2.1657

Pavlakis N; Kichenadasse G; Richardson G; Bowyer S; Andelkovic V; Ganju V; Tan A; Samol J; Thomas D; Fernandez AM; Paszkiewicz K; Ingram P; Boyd-Kirkup J; Kwek KY, 2024, 'P3.12D.09 Trial in Progress: A Phase Ib Study of HMBD-001, An Anti-HER3 Antibody, in Advanced Squamous Non-Small Cell Lung Cancer', Journal of Thoracic Oncology, 19, pp. s350, http://dx.doi.org/10.1016/j.jtho.2024.09.631

Sharaf R; Jin DX; Grady J; Napier C; Ebot E; Frampton GM; Albacker LA; Thomas DM; Montesion M, 2023, 'A pan-sarcoma landscape of telomeric content shows that alterations in RAD51B and GID4 are associated with higher telomeric content', Npj Genomic Medicine, 8, http://dx.doi.org/10.1038/s41525-023-00369-6

Lu CY; Terry V; Thomas DM, 2023, 'Precision medicine: affording the successes of science', Npj Precision Oncology, 7, http://dx.doi.org/10.1038/s41698-022-00343-y

Vaghjiani VG; Cochrane CR; Jayasekara WSN; Chong WC; Szczepny A; Kumar B; Martelotto LG; McCaw A; Carey K; Kansara M; Thomas DM; Walkley C; Mudge S; Gough DJ; Downie PA; Peacock CD; Matsui W; Watkins DN; Cain JE, 2023, 'Ligand-dependent hedgehog signaling maintains an undifferentiated, malignant osteosarcoma phenotype', Oncogene, 42, pp. 3529 - 3541, http://dx.doi.org/10.1038/s41388-023-02864-7

McNamee N; Lin F; Sim H-W; Napier C; Thomas D; Simes J; Thavaneswaran S, 2023, 'PATH-25. EXPLORING THE PROGNOSTIC IMPLICATIONS OF MOLECULAR ALTERATIONS IN ASTROCYTOMAS USING COMPREHENSIVE GENOMIC PROFILING (CGP)', Neuro-Oncology, 25, pp. v173 - v173, http://dx.doi.org/10.1093/neuonc/noad179.0655

Le Tourneau C; André F; Helland Å; Mileshkin L; Minnaard W; Schiel A; Taskén K; Thomas DM; Veronese ML; Durán-Pacheco G; Leyens L; Rufibach K; Thomas M; Krämer A, 2023, 'Modified study designs to expand treatment options in personalised oncology: a multistakeholder view', European Journal of Cancer, 194, http://dx.doi.org/10.1016/j.ejca.2023.113278

Ng JY; Warwick L; Craft P; Austen L; Ashford B; Gorddard N; Ballinger ML; Thomas DM; Blombery P; Tucker K; Polizzotto MN, 2023, 'Myelodysplastic syndrome and multiple solid tumours in an individual with compound heterozygous deleterious FANCM variants: A case report and review of the literature', British Journal of Haematology, 203, pp. 481 - 484, http://dx.doi.org/10.1111/bjh.19059

Zeverijn LJ; Looze EJ; Thavaneswaran S; van Berge Henegouwen JM; Simes RJ; Hoes LR; Sjoquist KM; van der Wijngaart H; Sebastian L; Geurts BS; Lee CK; de Wit GF; Espinoza D; Roepman P; Lin FP; Jansen AML; de Leng WWJ; van der Noort V; Leek LVM; de Vos FYFL; van Herpen CML; Gelderblom H; Verheul HMW; Thomas DM; Voest EE, 2023, 'Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials', International Journal of Cancer, 153, pp. 1413 - 1422, http://dx.doi.org/10.1002/ijc.34649

Harrison C; Bartley N; Jacobs C; Best M; Vatter S; Meiser B; Ballinger ML; Thomas DM; Butow P, 2023, 'Family communication and results disclosure after germline sequencing: A mixed methods study', Patient Education and Counseling, 114, http://dx.doi.org/10.1016/j.pec.2023.107800

Sabesan S; Malica M; Gebbie C; Scott C; Thomas D; Zalcberg J, 2023, 'Implementation of the Australasian Teletrial Model: Translating ideas into action using implementation science frameworks', Journal of Telemedicine and Telecare, 29, pp. 641 - 647, http://dx.doi.org/10.1177/1357633X211017805

Thavaneswaran S; Kansara M; Lin F; Espinoza D; Grady JP; Lee CK; Ballinger ML; Sebastian L; Corpuz T; Qiu MR; Mundra P; Bailey CG; Schmitz U; Simes J; Joshua AM; Thomas DM, 2023, 'A signal-seeking Phase 2 study of olaparib and durvalumab in advanced solid cancers with homologous recombination repair gene alterations', British Journal of Cancer, 129, pp. 475 - 485, http://dx.doi.org/10.1038/s41416-023-02311-0

Zeverijn LJ; Looze E; Thavaneswaran S; van Berge Henegouwen JM; Simes J; Hoes LR; Geurts B; Sebastian L; Roepman P; Lin FP-Y; Jansen AML; de Leng WWJ; van der Noort V; Leek LVM; De Vos FYFL; Verheul HMW; Gelderblom H; Thomas DM; Voest EE; Sjoquist KM, 2023, 'Clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials.', Journal of Clinical Oncology, 41, pp. 3101 - 3101, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.3101

Kansara M; Lin FP-Y; Thavaneswaran S; Napier CE; Grady JP; Ballinger ML; Simes J; Thomas DM, 2023, 'Genomic alterations associated with response to immune checkpoint inhibitors in rare cancers: A biomarker exploration study from the Australian Molecular Screening and Therapeutics (MoST) Program.', Journal of Clinical Oncology, 41, pp. 2594 - 2594, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.2594

Thavaneswaran S; Lin FP-Y; Napier CE; Grady JP; Ballinger ML; Kansara M; Grimison PS; Pavlakis N; Wong MK; Sjoquist KM; Goldstein D; Chantrill LA; Simes J; Thomas DM, 2023, 'Genomic targetability and survival outcomes of biliary tract cancers (BTC): A retrospective cohort study of the Australian Molecular Screening and Therapeutics (MoST) program.', Journal of Clinical Oncology, 41, pp. 4093 - 4093, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.4093

Lin FP-Y; Thavaneswaran S; Napier CE; Grady JP; Kansara M; Sebastian L; Kee D; Zaheed M; Millward M; Brown MP; Charakidis M; Craft PS; Grimison PS; Harrup RA; O'Byrne KJ; Desai J; Lee CK; Ballinger ML; Simes J; Thomas DM, 2023, 'Genomic therapy matching in rare and refractory cancers: Updated results from a retrospective cohort study in the Molecular Screening and Therapeutic (MoST) program.', Journal of Clinical Oncology, 41, pp. 1540 - 1540, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.1540

Zaheed M; Napier CE; Cops EJ; Ferris N; Moodie K; Milner B; Moses D; Poplawski N; Dow EG; Harris M; Tucker K; Trainer A; James P; Thomas DM; Ballinger ML, 2023, 'Long-term clinical and psychosocial outcomes of surveillance in Li Fraumeni syndrome.', Journal of Clinical Oncology, 41, pp. 10578 - 10578, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.10578

Kee D; Lin FP-Y; Thavaneswaran S; Napier CE; Harrison ML; Beale PJ; Lynch J; Davis AJ; Ananda S; Lombard JM; Friedlander M; Kansara M; Sebastian L; Lee CK; Ballinger ML; Simes J; Thomas DM, 2023, 'Molecular tumor profiling and therapy selection in advanced gynecological cancers: A retrospective cohort analysis from the Australian Molecular Screening and Therapeutics (MoST) Program.', Journal of Clinical Oncology, 41, pp. 5526 - 5526, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.5526

Thavaneswaran S; Mersiades A; Lin FP-Y; Espinoza D; Grady JP; Lee CK; Desai J; Brown MP; Grimison PS; O'Byrne KJ; Harrup RA; Nagrial A; Sebastian L; Chinchen S; Kansara M; Craft PS; Millward M; Simes J; Joshua AM; Thomas DM, 2023, 'Trastuzumab emtansine (T-DM1) in advanced cancers with HER2 mutations or amplification: Results from the Molecular Screening and Therapeutics (MoST) Program substudy.', Journal of Clinical Oncology, 41, pp. 3127 - 3127, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.3127

Stark Z; Boughtwood T; Haas M; Braithwaite J; Gaff CL; Goranitis I; Spurdle AB; Hansen DP; Hofmann O; Laing N; Metcalfe S; Newson AJ; Scott HS; Thorne N; Ward RL; Dinger ME; Best S; Long JC; Grimmond SM; Pearson J; Waddell N; Barnett CP; Cook M; Field M; Fielding D; Fox SB; Gecz J; Jaffe A; Leventer RJ; Lockhart PJ; Lunke S; Mallett AJ; McGaughran J; Mileshkin L; Nones K; Roscioli T; Scheffer IE; Semsarian C; Simons C; Thomas DM; Thorburn DR; Tothill R; White D; Dunwoodie S; Simpson PT; Phillips P; Brion MJ; Finlay K; Quinn MC; Mattiske T; Tudini E; Boggs K; Murray S; Wells K; Cannings J; Sinclair AH; Christodoulou J; North KN, 2023, 'Australian Genomics: Outcomes of a 5-year national program to accelerate the integration of genomics in healthcare', American Journal of Human Genetics, 110, pp. 419 - 426, http://dx.doi.org/10.1016/j.ajhg.2023.01.018

Back to profile page